Phosphodiesterase 5 (PDE5) inhibitors may be associated with a number adverse events involving the eye.
Patient selection: regular use of a phosphodiesterase 5 inhibitor
Adverse effects include:
(1) serous retinal detachment (SRD; adjusted incidence rate ratio 2.6)
(2) retinal vascular occlusion (RVO; adjusted incidence rate ratio 1.4)
(3) ischemic optic neuropathy (ION; adjusted incidence rate ratio 2.0)
A patient who is taking a PDE5 inhibitor needs to contact a physician if any visual deficit is experienced.
